[Encapsulation of atrial natriuretic peptide (ANP) cDNA transfection cells and ANP circadian expression].
OBJECTIVE
A technique based on the release of atrial natriuretic peptide (ANP) from encapsulated ANP cDNA transfected Chinese hamster ovary (CHO) cells for potential therapeutic approach to hypertension or congestive heart failure (CHF) was investigated.


METHODS
ANP cDNA transfected CHO cells were encapsulated in polycaprolactone (PCL) tubes and the levels of ANP secreted from PCL tubes were detected. Circadian rhythm of ANP secreted by encapsulated transfected cells was also studied by regulation with melatonin.


RESULTS
During culturing, the encapsulated cells remained viable and the mean level of ANP reached 246.1 pg/ml/24 h in 2 ml medium containing one PCL tube (20 mm in length and 3 mm in diameter), whereas the secretion by the control was negative. The secretion of ANP showed a circadian variation: higher at night, but lower at day. The acrophase of circadian rhythm was 4:18 and shifted to 7:56 after melatonin was given.


CONCLUSIONS
The above results demonstrated a potential use of the encapsulation technique of gene transfected cells implanted into human body for treatment of hypertension or CHF.
Chen
Li-guo
LG
Qu
Yi
Y
Xiao
Jing
J
Guo
Hui-ling
HL
Wan
Chao-min
CM
Wang
Zheng-rong
ZR
D000818:Animals; D009320:Atrial Natriuretic Factor / Q000008:administration & dosage* / Q000235:genetics / Q000378:metabolism / Q000627:therapeutic use; D016466:CHO Cells / Q000166:cytology / Q000378:metabolism* / Q000502:physiology; D002208:Caproates; D002940:Circadian Rhythm / Q000187:drug effects / Q000502:physiology*; D006224:Cricetinae; D016503:Drug Delivery Systems; D015195:Drug Design; D006333:Heart Failure / Q000188:drug therapy*; D006973:Hypertension / Q000188:drug therapy*; D007150:Immunohistochemistry; D007783:Lactones; D008550:Melatonin / Q000494:pharmacology; D014162:Transfection
D002208:Caproates; D007783:Lactones; C121056:caprolactone; D009320:Atrial Natriuretic Factor; D008550:Melatonin